London, 2 January 2014 – ViiV Healthcare today announced that it will participate in a new scientific data sharing initiative – accessed online at – which has been set up to enable researchers to request access to anonymised patient level data and supporting documents from clinical trials. The list of ViiV Healthcare studies that will be initially included has been drawn from ViiV Healthcare’s own clinical trial register (

The set of past studies listed in this new initiative extends to globally-sponsored interventional phase II-IV clinical studies of approved medicines in ViiV Healthcare’s portfolio, in adults living with HIV. ViiV Healthcare will update and expand the list of studies described on the site. In addition, researchers can now enquire about the availability of data from other ViiV Healthcare clinical studies that are not listed on the site before submitting a research proposal.

With request technology powered by ideaPoint, the initiative is a collaboration involving a number of companies. All requests to access data will be reviewed by an independent panel who will ensure that the proposed research has scientific merit. In this way, researchers will be able to select studies from multiple sponsors via a single research proposal and a user-friendly online portal.

For more information, please refer to or the media contacts listed below.

About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a 10% shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit

About ideaPoint
ideaPoint, Inc. is an enterprise software provider. Since its launch in 2008, ideaPoint has delivered software solutions to industry-leading Pharmaceutical, Biotechnology and Medical Device organizations to capture and assess opportunities for collaboration.
ViiV UK/U.S.

Media enquiries
Rebecca Hunt +44 (0) 20 8380 6275; Marc Meachem +1 919 483 8756

Cautionary statement regarding forward-looking statements: GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under Item 3.D “Risk factors” in the company's Annual Report on Form 20-F for 2012.

Media contacts

For our corporate press office, email: Rachel Jaikaran

OR call +44 7823 523 755

For US-specific media enquiries,

OR call +1 919 605 4521

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.